Skip to main content

Adam Feuerstein

Articles From This Author

Goodbye
STOCKS

Goodbye

By Adam Feuerstein
Jun 13, 2017 1:01 PM EDT
Wednesday's Worst Stocks: AMC, JWN, PXD
STOCKS
CYTR

Goodbye CytRx, Your Game Is Over

By Adam Feuerstein
Jun 5, 2017 11:55 PM EDT
Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal
STOCKS
JUNOKITENVS

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

By Adam Feuerstein
Jun 5, 2017 9:00 AM EDT
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
STOCKS
RHHBYPBYI

'APHINITY' Study Spells Trouble for Roche, Another Win for Puma Bio

By Adam Feuerstein
Jun 5, 2017 7:30 AM EDT
Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free
STOCKS
BLUECELG

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

By Adam Feuerstein
Jun 5, 2017 7:30 AM EDT
Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals
STOCKS
INCYMRK

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

By Adam Feuerstein
Jun 4, 2017 6:22 PM EDT
Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17
STOCKS
INCYMRKBMY

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17

By Adam Feuerstein
Jun 3, 2017 9:00 AM EDT
Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors
STOCKS
LOXOMRK

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors

By Adam Feuerstein
Jun 3, 2017 7:30 AM EDT
Cramer: Top 10 Bull Markets Right Now (Part 2)
STOCKS
PBYIGSKRHHBY

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

By Adam Feuerstein
May 25, 2017 11:18 AM EDT
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories
STOCKS

Puma Bio FDA Advisory Panel Live Blog

By Adam Feuerstein
May 24, 2017 7:41 AM EDT
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories
STOCKS
PBYI

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

By Adam Feuerstein
May 22, 2017 10:41 AM EDT
AveXis, Esperion and Amgen Among Biotech Movers
STOCKS
AMGNRDUS

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

By Adam Feuerstein
May 22, 2017 9:44 AM EDT
Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential
STOCKS
LJPC

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

By Adam Feuerstein
May 22, 2017 7:13 AM EDT
Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed
STOCKS
MRKBMYNLNK

Incyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed

By Adam Feuerstein
May 18, 2017 1:03 PM EDT
Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting
STOCKS
BLUEJUNOKITE

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

By Adam Feuerstein
May 17, 2017 5:10 PM EDT
Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend
STOCKS
MRK

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend

By Adam Feuerstein
May 17, 2017 5:05 PM EDT
Allergan, Celgene Offer Solid Biotech Value
STOCKS
CELGAGIO

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

By Adam Feuerstein
May 17, 2017 5:02 PM EDT
Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
STOCKS
AKBAFGEN

Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact

By Adam Feuerstein
May 15, 2017 4:05 PM EDT
French Authorities Suspend AB Science Clinical Trials, Days Before ALS Drug Data Reveal
STOCKS

French Authorities Suspend AB Science Clinical Trials, Days Before ALS Drug Data Reveal

By Adam Feuerstein
May 12, 2017 8:29 AM EDT
Wake Up Wall Street: Stocks Poised for Modest Pullback as Trump Travels to Italy for G-7 Summit
STOCKS
XBIT

XBiotech No. 2 Executive Resigns, Leaving Struggling Biotech Without Top Operations Chief

By Adam Feuerstein
May 11, 2017 8:31 AM EDT
Merck Is Dangerously Close to a Breakdown
STOCKS
MRKAZNRHHBY

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

By Adam Feuerstein
May 10, 2017 5:29 PM EDT
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
STOCKS
RHHBYMRKBMY

The Cancer Immunotherapy Fallout from Roche's Bladder Cancer Failure

By Adam Feuerstein
May 10, 2017 4:02 PM EDT
AB Science Seeks to Shed Skepticism With ALS Drug Data Reveal
STOCKS

AB Science Seeks to Shed Skepticism With ALS Drug Data Reveal

By Adam Feuerstein
May 9, 2017 8:26 AM EDT
Kite Pharma Discloses CAR-T Patient Death, Rattling Investors
STOCKS
KITEJUNO

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors

By Adam Feuerstein
May 8, 2017 10:06 AM EDT
After $50 billion Eyewear Deal, Luxottica Will Now Dominate People's Faces Globally
STOCKS
TXMD

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

By Adam Feuerstein
May 8, 2017 9:14 AM EDT
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories
STOCKS
PBYI

A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories

By Adam Feuerstein
May 5, 2017 6:53 AM EDT
Zafgen Rebounds With a Safer Obesity Drug Targeting Diabetics
STOCKS
ZFGN

Zafgen Rebounds With a Safer Obesity Drug Targeting Diabetics

By Adam Feuerstein
May 4, 2017 4:05 PM EDT
Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers
STOCKS
CLVSTSROAZN

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

By Adam Feuerstein
May 4, 2017 1:29 PM EDT
No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come
STOCKS
GILD

No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come

By Adam Feuerstein
May 3, 2017 6:47 PM EDT
Home Construction Sector Is Moving Well
STOCKS
NTRPCVM

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

By Adam Feuerstein
May 3, 2017 2:58 PM EDT
Intra-Cellular Evades Scrutiny on Schizophrenia Drug Safety, Shares Plunge
STOCKS
ITCI

Intra-Cellular Evades Scrutiny on Schizophrenia Drug Safety, Shares Plunge

By Adam Feuerstein
May 1, 2017 11:22 AM EDT
Neurotrope Spins a Failed Alzheimer's Drug Study
STOCKS
NTRP

Neurotrope Spins a Failed Alzheimer's Drug Study

By Adam Feuerstein
May 1, 2017 7:18 AM EDT
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
STOCKS
SRPTSNY

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

By Adam Feuerstein
Apr 28, 2017 8:34 AM EDT
Acorda Therapeutics Sinks on Invalidated Patents
HEALTH
ALXN

Alexion Rises More Than 5% After Beating Consensus

By Adam Feuerstein
Apr 27, 2017 9:48 PM EDT
French Authorities Suspend AB Science Clinical Trials, Days Before ALS Drug Data Reveal
STOCKS
ACOR

Acorda Shares Fall in an Earnings Miss

By Adam Feuerstein
Apr 27, 2017 9:38 PM EDT
Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year
STOCKS
BMRN

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year

By Adam Feuerstein
Apr 27, 2017 4:36 PM EDT
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
STOCKS
ACORALXNAZN

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

By Adam Feuerstein
Apr 27, 2017 4:07 PM EDT
Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
STOCKS
AKBAAUPHFGEN

Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy

By Adam Feuerstein
Apr 26, 2017 10:59 AM EDT
M&A-Hungry Nestle Looking at Baby Food Maker Mead Johnson
STOCKS
AVXSIONSBIIB

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

By Adam Feuerstein
Apr 26, 2017 7:42 AM EDT
Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
STOCKS
AKBAFGEN

Akebia Expands Anemia Pill Partnership to Include Europe, China Rights

By Adam Feuerstein
Apr 25, 2017 4:25 PM EDT
The 10 Worst-Performing S&P 500 Stocks in June
STOCKS
BIIB

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

By Adam Feuerstein
Apr 25, 2017 9:34 AM EDT
The 10 Worst-Performing S&P 500 Stocks in June
STOCKS
BIIBIONS

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boosts Sales

By Adam Feuerstein
Apr 24, 2017 8:50 AM EDT
Wednesday's Worst Stocks: AMC, JWN, PXD
STOCKS
TXMDPFEAGN

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

By Adam Feuerstein
Apr 21, 2017 8:27 AM EDT
XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection
STOCKS
XBIT

XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection

By Adam Feuerstein
Apr 21, 2017 8:00 AM EDT
Gold Rally Is Just Getting Started
STOCKS
TSROCLVS

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

By Adam Feuerstein
Apr 19, 2017 4:47 PM EDT
Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger
STOCKS
NVLSVRXKITE

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

By Adam Feuerstein
Apr 18, 2017 5:03 PM EDT
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories
STOCKS
PBYISPPICLVS

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

By Adam Feuerstein
Apr 18, 2017 1:31 PM EDT
Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K
STOCKS
NWBO

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

By Adam Feuerstein
Apr 18, 2017 8:52 AM EDT
Novartis' CAR-T Gene Therapy Receives FDA Approval
STOCKS
NVSKITE

Novartis Snags Coveted FDA 'Breakthrough" Label for CAR-T, Trial Results Still Under Wraps

By Adam Feuerstein
Apr 18, 2017 7:05 AM EDT
How to Trade Gilead, Parsley Energy, Twitter and More
REGULATION
GILDABBVAMGN

Gilead, Pfizer, AbbVie Win From Lilly's Loss

By Adam Feuerstein
Apr 17, 2017 10:51 AM EDT